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Abstract
Background: Osteosarcoma is the most common malignant bone tumour. Due to the high metastasis rate and
drug resistance of this disease, multi-drug regimens are necessary to control tumour cells at various stages of the
cell cycle, eliminate local or distant micrometastases, and reduce the emergence of drug-resistant cells. Many
adjuvant chemotherapy protocols have shown different efficacies and controversial results. Therefore, we classified
the types of drugs used for adjuvant chemotherapy and evaluated the differences between single- and multi-drug
chemotherapy regimens using network meta-analysis.
Methods: We searched electronic databases, including PubMed (MEDLINE), EmBase, and the Cochrane Library,
through November 2016 using the keywords “osteosarcoma”, “osteogenic sarcoma”, “chemotherapy”, and “random*”
without language restrictions. The major outcome in the present analysis was progression-free survival (PFS), and the
secondary outcome was overall survival (OS). We used a random effect network meta-analysis for mixed multiple
treatment comparisons.
Results: We included 23 articles assessing a total of 5742 patients in the present systematic review. The analysis of PFS
indicated that the T12 protocol (including adriamycin, bleomycin, cyclophosphamide, dactinomycin, methotrexate,
cisplatin) plays a more critical role in osteosarcoma treatment (surface under the cumulative ranking (SUCRA) probability 76.
9%), with a better effect on prolonging the PFS of patients when combined with ifosfamide (94.1%) or vincristine (81.9%).
For the analysis of OS, we separated the regimens to two groups, reflecting the disconnection. The T12 protocol plus
vincristine (94.7%) or the removal of cisplatinum (89.4%) is most likely the best regimen.
Conclusions: We concluded that multi-drug regimens have a better effect on prolonging the PFS and OS of
osteosarcoma patients, and the T12 protocol has a better effect on prolonging the PFS of osteosarcoma
patients, particularly in combination with ifosfamide or vincristine. The OS analysis showed that the T12
protocol plus vincristine or the T12 protocol with the removal of cisplatinum might be a better regimen for
improving the OS of patients. However, well-designed randomized controlled trials of chemotherapeutic
protocols are still necessary.
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Background
Osteosarcoma is the most common type of primary malig-
nant bone tumour. It exhibits a high metastasis rate and is
frequently detected in adolescents at sites of rapid bone
growth [1, 2]. Although osteosarcoma is frequently treated
by surgical joint amputation or disconnection, the progno-
sis remains poor in patients with metastatic osteosarcoma
[3]. Therefore, the ultimate treatment of this disease not
only depends on primary tumour control but also the re-
moval of small metastases. Thus, adjuvant chemotherapy
combined with the surgical removal of the primary
tumour is needed to reduce the size of the tumour, clear
the metastases, and improve progression-free survival
(PFS) and overall survival (OS).
Osteosarcoma is also a relatively drug-resistant
tumour, and the treatment effect of single-drug
chemotherapy is not ideal [4, 5]. Thus, multi-drug
regimens are necessary to control tumour cells at
various stages of the cell cycle, eliminate local or dis-
tant micrometastases, and reduce the emergence of
drug-resistant cells [6]. Several systematic reviews
have examined osteosarcoma chemotherapy, but the
results are controversial. A previous study suggested
that ifosfamide-based chemotherapy could significantly
improve the PFS and OS of osteosarcoma patients
[7]. However, recent traditional meta-analyses have
not determined whether ifosfamide application and
chemotherapy have similar histological response rates
and 5-year PFS and OS in non-metastatic and
primary osteosarcoma patients; thus, ifosfamide is not
recommended [8–10]. Additionally, in a systematic re-
view concerning the dose of chemotherapy drugs, high-
dose drugs did not significantly improve the PFS and OS
of patients compared to moderate-dose drugs [11–13].
Thus, additional studies are needed to resolve these
controversies.
From the 1970s to the present, many adjuvant chemo-
therapy protocols have shown various efficacy differ-
ences and controversial results. No definitive evidence
exists regarding which treatment is more advantageous
for clinical application [14, 15]. The aim of the present
study was to analyse the existing chemotherapy protocol
through direct and indirect comparisons to guide clinical
application. However, an analysis of each type of chemo-
therapy protocol is too complex and cumbersome.
Therefore, in the present study, we classified the types of
drugs used in adjuvant chemotherapy and evaluated the
differences between single or multi-drug chemotherapy
regimens using a network meta-analysis.
Methods
This network meta-analysis was performed in accor-
dance with Preferred Reporting Items for Systematic
Reviews (PRISMA) statement [16].
Data search strategy and selection criteria
Two authors independently performed the literature search
through November 2016 using electronic databases, inclu-
ding PubMed (MEDLINE), EmBase, and the Cochrane
Library, with the keywords “osteosarcoma”, “osteogenic sar-
coma”, “chemotherapy”, and “random*”, without language
restriction. The bibliographies of the obtained publications
and relevant reviews were also assessed to ensure that no
relevant studies were inadvertently omitted. The publica-
tions included in the present study met the following
criteria: (1) randomized controlled trial (RCT) design; (2)
inclusion of osteosarcoma patients; (3) examination of two
or more groups using different single- or multi-drug
regimens; and (4) inclusion of PFS or OS as an outcome.
The exclusion criteria consisted of the following: (1) non-
RCT studies; (2) studies including patients with other types
of sarcomas, such as Ewing sarcoma; (3) non-
chemotherapy controlled studies, such as surgery or radio-
therapy controlled studies; (4) studies comparing the same
chemotherapeutic drug type, such as a drug dose-related
study; and (5) non-desired outcome studies. Additionally,
reviews, comments, case reports, basic studies, and con-
ference reports were also excluded.
Data extraction
Two authors independently extracted the following
information from eligible studies: first author’s name,
publication year, location, research time, study register
or abbreviation, sample size, average age, ratio of
males, type of disease, experimental intervention, con-
trol, and follow-up. In the present analysis, the major
outcome was PFS, and the secondary outcome was
OS, as some patients changed the initial randomized
treatment after disease progression. We assessed the
methodological quality of the included trials using the
Cochrane Collaboration’s tool, which assigns grades of
“high risk”, “unclear risk”, or “unclear risk” of bias
across the seven specified domains [17].
Statistics analysis
We initially conducted a pairwise meta-analysis using a
random effect model, as this model is likely the most
appropriate and conservative methodology accounting for
between-trial heterogeneity within each comparison [18].
For dichotomous outcomes, odds ratios (ORs) or loga-
rithm transformation with 95% confidence intervals (CIs)
were calculated to determine the sizes of the effects. We
also used a random effect network meta-analysis for mixed
multiple treatment comparisons because this analysis fully
preserves the within-trial randomized treatment compari-
sons in each trial [19]. To rank the treatments for each out-
come, we used the surface under the cumulative ranking
(SUCRA) probabilities [20]. Comparison-adjusted funnel
plots were used to determine whether small-study effects
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Table 1 Characteristics of subjects in eligible studies













Yan Zhang [22] 2013 China 2007–2008 NA 76 24.4 ± 1.7 44/32 Enneking II-III 5 years
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11//9 Postrelapse 73 months
J.S. Whelan [27] 2012 Europe 1982–2002 EOI
(BO02/80831)





High grade 9.4 years





Alexander J. Chou [29] 2009 USA 2001–2005 CCG/POG
(INT-0133)



















High grade 77 months




42/31 High grade 91.4 months







Michael P. Link [34] 1993 International 1982–1984 MIOS 36 NA NA High grade,
Non-metastasis
4–8 years




K. Winkler [36] 1984 Germany 1979–1982 COSS-80 116 14
(5–24)
69/47 High grade 30 months
F. Eilber [37] 1987 USA 1981–1984 NA 112 15
(4–75)
44/15 Non-metastasis 2 years




K. Winkler [39] 1988 Germany 1982–1984 COSS-82 125 14 73/52 Osteosarcoma 6 years
Vivien H.C. Bramwell [40] 1992 Canada 1983–1986 EOI 198 NA 114/84 High grade 5 years
John C. Ivins [41] 1976 USA 1974–1975 Mayo Clinic 26 NA NA Osteosarcoma 15 months
C. Jasmin [42] 1978 France 1976- EORTC 27 18
(9–28)
13/14 Osteosarcoma 2 years
Gilchrist GS [43] 1978 USA NA NA 32 NA NA Osteosarcoma 753 days
J.M.V. Burgers [44] 1988 Netherlands 1978–1983 EORTC-SIOP03
(20781)
140 1–30 87/53 Osteosarcoma 5 years
Abbreviations: CCG Children’s Cancer Group, COSS Cooperative Osteosarcoma Study Group, EOI the European Osteosarcoma Intergroup, EORTC European
Organization for Research on Treatment of Cancer, EURAMOS-1 The European and American Osteosarcoma Study Group, MIOS the Multi-institutional Osteosarcoma
Study, MSKCC Memorial Sloan-Kettering Cancer Center, SFOP Societe Francaise d’Oncologie Pediatrique, SSG the Scandinavian Sarcoma Group, NA not available
aMean ± standardization; median (minimum-maximum); minimum-maximum
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were present in the analysis conducted in the present study
[21]. All tests were two-tailed, and a p value of less than 0.05
was considered statistically significant. Data analyses were
performed using STATA software (version 14.0; Stata
Corporation, College Station, TX, USA).
Results
Literature search
In the present study, 747 articles were identified after
the duplicates were removed. A total of 678 articles
were excluded after the titles and abstracts were
screened. The full texts of the remaining 69 articles
were assessed, and the following types of studies were
removed: non-randomized design (19); comparisons of
the same type of chemotherapeutic drug (12); duplica-
tions or secondary studies (9); non-controlled studies
(2); no desired outcomes (2); and other sarcoma stu-
dies (2). Eventually, 23 articles assessing a total of
5742 patients were included in the present systematic
review [22–44] (Fig. 1, Table 1).
The included studies were published from 1976 to
2016 and were researched from 1974 to 2014. The ana-
lysis contained several multicentre large-scale studies,
such as The European and American Osteosarcoma
Study Group-1 (EURAMOS-1), Osteosarcoma 2006
(OS2006), and the Symposium of the Cooperative
Osteosarcoma Study Group (COSS-80). Many studies
contained duplicate reports. Thus, we included relatively
recently published studies and referred to the outcomes
of the duplicate reports. All age groups of patients were
included, and slightly more men than women were in-
cluded. All studies included patients with osteosarcoma
defined according to a pathological diagnosis. In
addition, four studies included osteosarcoma patients
without metastasis, two studies included metastasis
patients, and one study included relapse patients. Most
studies initiated chemotherapy prior to surgery. The
longest median follow-up period was 9.4 years (Table 1).
All included studies had an RCT design without
blinding, and most randomizations were not rigorous.
However, the assessed outcome was objective; thus, the
overall quality of the included studies was not ideal but
was acceptable (Additional file 1: Figure S1).
For chemotherapeutic drug application, we investi-
gated all types of drugs used in the intervention arms
and classified each of the drugs of the experimental arms
Fig. 1 PRISMA flowchart illustrating the selection of studies included in the present analysis
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by alphabetical order. The present study did not include
a comprehensive analysis, reflecting the characteristics
of applied chemotherapeutic protocols, as most applica-
tion stages, durations, and dosages of drugs were differ-
ent in different protocols (Table 2). Drugs showing no
chemotherapeutic effect, such as granulocyte colony-
stimulating factor (G-CSF) and muramyl tripeptide, were
excluded. Drugs that may be included in chemotherapy,
such as mistletoe, were included in the present analysis.
For the PFS analysis, we extracted all studies of 5-year
PFS or the longest follow-up period for PFS. In the
present study, we analysed 16 types of multi-drug regi-
mens. Four multi-drug regimens were directly compared
to a blank control, which indicated treatment without
chemotherapy. In this analysis, the nodes were weighted
according to the number of studies evaluated for each
treatment, and the edges were weighted according to the
precision of the direct estimate for each pairwise com-
parison (Fig. 2a). In network pairwise comparisons, the
ABCDM (all protocol abbreviations are defined in
Table 2) regimen was superior to the ACML (logOR,
1.38; 95% CI, 0.09–2.68) and Blank (logOR, 1.30; 95%
CI, 0.19–2.41) regimens for the PFS outcome. The
ABCDMP regimen was superior to the ACML (logOR,
2.14; 95% CI, 0.45–3.84), AML (logOR, 2.13; 95% CI,
0.00–4.26), Blank (logOR, 2.06; 95% CI, 0.50–3.62), and
ML regimens (logOR, 2.24; 95% CI, 0.22–4.27), and the
ABCDMPI regimen, combining ABCDMP with ifosfa-
mide, was superior to the ABCDMP regimen alone
(logOR, 0.84; 95% CI, 0.09–1.59). The ABCDMPI regi-
men was also superior to the ACML (logOR, 2.98; 95%
CI, 1.13–4.84), AML (logOR, 2.97; 95% CI, 0.71–5.23),
Blank (logOR, 2.90; 95% CI, 1.17–4.63), ML (logOR,
3.08; 95% CI, 0.92–5.24), and N (logOR, 2.75; 95% CI,
0.22–5.28) regimens in the network comparisons. More-
over, the ABCDMP regimen in combination with vin-
cristine (ABCDMPL) was superior to the ACML (logOR,




Fig. 2 Network of comparisons for all outcomes included in the analyses. a Progression-free survival. b Overall survival, part one. c Overall survival,
part two. Abbreviations: A adriamycin, B bleomycin, C cyclophosphamide, D dactinomycin, E etoposide, F interferon, I ifosfamide, K alkeran, L
vincristine, M methotrexate, N transfer factor, P cisplatin
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0.01–0.90), AMPF (logOR, 0.64; 95% CI, 0.11–1.18), and
Blank (logOR, 1.80; 95% CI, 0.19–3.42) regimens. No
other significant differences were found among these
regimens (Additional file 2: Table S1). Based on the
SUCRA rank, the ABCDMPI regimen was the most
likely treatment to improve PFS in osteosarcoma pa-
tients (94.1%), followed by the ABCDMPL (81.9%) and
ABCDMP (76.9%) regimens. Additionally, the comparison-
adjusted funnel plot used to assess publication bias and
determine the presence of small-study effects did not sug-
gest any publication bias (Additional file 3: Figure S2a). In
addition, some regimens were not included in the network
meta-analysis, reflecting a disconnection, and a traditional
meta-analysis showed no significant difference between in-
terventions, except for APIZ compared to MIE (OR, 2.27;
95% CI 1.02–5.04) (Fig. 3).
For the OS analysis, we separated the regimens into
two groups, reflecting the disconnection. The first group
included AMP, AMPF, AMPI, AMPIE, AP, and
ABCDMPL. Four regimens were directly compared to
AMP, and we directly compared AP and ABCDMPL
(Fig. 2b). In the network comparisons, the ABCDMPL
regimen showed a significant advantage compared to the
AMP (logOR, 0.47; 95% CI, 0.02–0.92), AMPF (logOR,
0.65; 95% CI, 0.01–1.29), and AP (logOR, 0.31; 95% CI,
0.04–0.57) regimens (Additional file 4: Table S2). The
results showed that ABCDMPL was most likely the best
regimen for improving the OS (94.7%) of osteosarcoma
patients, followed by the AP (58.3%) and AMPIE (56.8%)
regimens. The second group included ABCDM,
ABCDMP, ACML, BCDM, ML, and N. Four regimens
were directly compared to the Blank condition (Fig. 2c).
In the network comparison, the ABCDM regimen was
superior to the AML (logOR, 1.99; 95% CI, 0.14–3.84),
Blank (logOR, 1.54; 95% CI, 0.37–2.70), and ML (logOR,
1.76; 95% CI, 0.03–3.49) regimens, and no other
significant difference was found among comparisons
(Additional file 5: Table S3). Regarding rank, ABCDM
(89.4%) was most likely to be the best regimen, followed
by N (70.1%) and BCDM (60.9%). The comparison-
adjusted funnel plot showed no obvious publication bias
(Additional file 3: Figure S2b and c). A comparison of
regimens not included in the network meta-analysis re-
vealed that APIR had a significant advantage over API in
improving the OS (OR, 3.48; 95% CI, 1.17–10.32) of the
patients (Fig. 3). However, this result was based on a single
study and lacked precision and robustness.
Discussion
In the present study, we analysed single- or multi-
drug regimens of chemotherapy for the treatment of
osteosarcoma using a network meta-analysis. We did
Fig. 3 Forest plot of comparisons not included in the network meta-analysis. Abbreviations: A adriamycin, E etoposide, I ifosfamide, M methotrexate,
P cisplatin, R recombinant human endostatin, T pirarubicin, V Viscum album, Z zoledronate
Wang et al. Journal of Orthopaedic Surgery and Research  (2017) 12:52 Page 6 of 11
Table 2 Interventions and abbreviations for eligible studies
Author Year Study register/short
name
Intervention Abbr. Control Abbr.




























Alessandra Longhi [26] 2014 EudraCT:
2006-002676-18
Viscum album V Etoposide E










ABCDMPL Adriamycin; cisplatin AP
Hui Zhao [28] 2010 NA Cisplatin; pirarubicin PT Ifosfamide; pirarubicin IT














Marie-Cecile Le Deley [31] 2007 SFOP-OS94
(NCT00180908)
Adriamycin; methotrexate AM Methotrexate; ifosfamide;
etoposide
MIE















ABCDMPL Adriamycin; cisplatin AP




John H. Edmonson [35] 1984 Mayo Clinic Methotrexate; vincristine ML Blank Blank































Vivien H.C. Bramwell [40] 1992 EOI Adriamycin; methotrexate; cisplatin AMP Adriamycin; cisplatin AP
John C. Ivins [41] 1976 Mayo Clinic Transfer factor N Adriamycin;
methotrexate; vincristine
AML
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not analyse the chemotherapeutic effect according to
protocols because the application stage, duration, and
dosage of each drug varied. The PFS analysis showed
that the ABCDMPI, ABCDMPL, and ABCDMP regi-
mens were most likely to improve PFS in osteosar-
coma patients. In the present study, the ABCDMP
regimen played a critical role in a treatment involving
the T12 protocol (including adriamycin, bleomycin,
cyclophosphamide, dactinomycin, methotrexate, cis-
platin) used at the Memorial Sloan Kettering Cancer
Center (MSKCC) between 1986 and 1993. This more
intensive preoperative regimen comprised two courses
of cisplatinum and doxorubicin in addition to a high
dose of methotrexate and bleomycin, cyclophospha-
mide, and dactinomycin [32]; it showed a better effect
on prolonging the PFS of patients when combined with
ifosfamide or vincristine. However, these results are par-
tially supported by a previous view that ifosfamide-based
chemotherapy significantly improves the PFS of osteosar-
coma patients [7]. In the secondary outcome analysis, we
also observed that the regimens with more types of drugs
showed better results, but use of a transfer factor also
showed advantages. However, these results should be
considered with caution, as most studies changed the initial
protocol and required more active chemotherapy with me-
tastasis or progression. Therefore, the effective gap between
interventions could be reduced, resulting in bias. The
practice of changing the chemotherapy regimen is
common, correct, and ethical in clinical practice.
Despite the present results, it is undeniable that
when the number of different types of chemothera-
peutic drugs increases, the cytotoxicity and adverse
effects will also simultaneously increase. Thus, a bal-
ance exists, suggesting that multi-drug regimens could
significantly prolong the PFS of osteosarcoma patients
but lead to more serious adverse effects. Adverse
effects are common in chemotherapy and include
nephrotoxicity, ototoxicity, and bone marrow suppres-
sion. Serious adverse effects will affect the application
of the chemotherapy programme and even the quality
of life of patients.
Thus, in clinical practice, cytoprotective agents, such as
muramyl tripeptide, are also frequently and simultaneously
used for chemotherapy. However, this agent is not widely
used, and the literature did not show that cytoprotective
agents significantly improved the PFS and OS of patients
[29]. Therefore, in the present study, we did not analyse the
use of cytoprotective agents. In addition, Viscum album,
transfer factor, and recombinant human endostatin are non-
traditional chemotherapy drugs that show a cytotoxicity
effect. Although they are controversial, we still included
these types of drugs in the present analysis.
In the present study, neoadjuvant chemotherapy was
used in most included studies. Neoadjuvant chemotherapy
includes the administration of chemotherapeutic agents
prior to the main treatment, and this regimen has several
advantages: (1) It can eliminate micrometastases early to
avoid metastases caused by delayed surgery or low resist-
ance. (2) It can control the primary tumour and reduce
the chance of surgical tumour spread. (3) It can assess the
chemotherapeutic effect and guide the postoperative
chemotherapy. (4) It can assess the prognosis earlier.
Although the results of RCTs suggested no significant
effect on the outcome of patients when comparing pre-
operative chemotherapy to postoperative chemotherapy
[45], neoadjuvant chemotherapy for limb salvage and the
surgical process is still worthy of clinical application.
In addition, several studies compared intra-arterial or
intravenous chemotherapeutic infusion. When the same
regimens were applied, no significant differences were ob-
served in the chemotherapy response between intra-arterial
and intravenous infusion [46, 47]. However, some studies
suggested that intra-arterial infusion has a more active ef-
fect [48, 49]. Regarding the dosage of chemotherapeutic
agents, comparisons of a high or moderate dose of metho-
trexate have primarily been described. A high dose of
methotrexate was more widely used in patients who could
tolerate this drug. However, in small-sample RCTs of
children with osteosarcoma, a significant difference in out-
come was not observed between different dosages [50–52].
We systematically analysed chemotherapeutic regi-
mens for osteosarcoma patients using a network
Table 2 Interventions and abbreviations for eligible studies (Continued)







Gilchrist GS [43] 1978 NA Adriamycin; methotrexate;
vincristine
AML Transfer factor N





Abbreviations: CCG Children’s Cancer Group, COSS Cooperative Osteosarcoma Study Group, EOI the European Osteosarcoma Intergroup, EORTC European
Organization for Research on Treatment of Cancer, EURAMOS-1 The European and American Osteosarcoma Study Group, MIOS The Multi-institutional
Osteosarcoma Study, MSKCC Memorial Sloan Kettering Cancer Center, SFOP Societe Francaise d’Oncologie Pediatrique, SSG the Scandinavian Sarcoma Group,
NA not available
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meta-analysis, although individual chemotherapeutic
protocols could not be analysed. In the present study,
multi-drug regimens, such as the T12 protocol plus
ifosfamide or vincristine, had a better effect on
prolonging the PFS and OS of osteosarcoma patients.
Further research with well-designed, double-blinded
RCTs is still necessary, as the psychological evidence
might also influence patient outcomes. In addition,
further trials using relatively well-developed chemo-
therapeutic protocols would be beneficial to analyse
the differences among multiple chemotherapeutic
protocols.
Limitations
There are several limitations to the present study. First,
the present analysis was performed at a study level, not at
an individual level. Second, for chemotherapy, cytoprotec-
tive agents might also improve the survival time of
patients by reducing the chemotherapy-induced damage
to normal tissue, but these drugs were not analysed in this
study. Third, we did not perform the Grading of Recom-
mendations Assessment, Development and Evaluation in
the present analysis, as all included studies had an RCT
design without blind concealment, and most of the results
showed a low risk of imprecision.
Conclusions
In conclusion, the T12 protocol has a better effect on
prolonging the PFS of osteosarcoma patients when com-
bined with ifosfamide or vincristine. For the OS, the T12
protocol plus vincristine or the removal of cisplatinum also
represents the best regimen. Further RCTs of chemothera-
peutic protocols are still necessary.
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